Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases
Abstract
Leptomeningeal metastases (LMs) occur in 3% to 9% of NSCLC cases, with a limited survival (∼3 mo) in patients with wild-type NSCLC, and up to 12 months for patients with a targetable genomic alteration.1 Therefore, there is a clinical need for identifying new therapies for these patients with...
Paper Details
Title
Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases
Published Date
Jan 1, 2021
Volume
2
Issue
1
Pages
100096 - 100096
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History